James L. Gulley, MD, PhD, FACP
Chief, Genitourinary Malignancies Branch at National Cancer Institute (NCI)
Dr. James Gulley is an internationally recognized expert in immunotherapy for cancer. He graduated from Loma Linda University in California with a PhD in microbiology in 1994 and an MD in 1995. As part of this eight-year MD/PhD Medical Scientist Training Program he completed a dissertation on tumor immunology. He completed his residency in internal medicine at Emory University in 1998, followed by a medical oncology fellowship at the NCI. Since 1999 he has authored and run a variety of clinical trials at the NCI, serving as principal investigator or an associate investigator on approximately 60 trials.
Dr. Gulley is especially interested in immunotherapy for prostate cancer. As Director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology, he takes promising laboratory findings and uses them to design and conduct clinical trials. These innovative investigator-initiated studies involve the use of cancer vaccines and other immunostimulatory agents to modulate the immune response in cancer patients, and the addition of other strategies to enhance vaccine-mediated killing. In particular, he played a pivotal role in the clinical development of a prostate cancer vaccine, created in the National Cancer Institute, and serves as the principal Investigator on a global Phase III randomized clinical trial (Prospect) of this vaccine.
He is also a senior investigator within the Medical Oncology Branch at the National Cancer Institute. Dr. Gulley has received numerous awards including the 2010 Presidential Early Career Award for Scientists and Engineers (PECASE), the highest award bestowed by the US government on outstanding scientists early in their careers. He serves on many boards and committees. He has authored approximately 160 scientific papers and book chapters, edited 4 books and has made numerous invited presentations at national and international meetings.